We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cortical myoclonic tremor after chimeric antigen receptor T-cell therapy.
- Authors
Swinnen, Bart E. K. S.; van Rootselaar, Anne-Fleur; Spanjaart, Anne M.; de Bie, Rob M. A.; Kersten, Marie J.; van de Beek, Diederik; Brouwer, Matthijs C.; Dijk, Joke M.
- Abstract
Dear Sirs, Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and effective treatment of hematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL) [[1]-[3]]. The cortical myoclonic tremor resolved over the course of one to three months in three patients, and progressively improved until last follow-up (i.e., death nine months after CAR T-cell therapy) in one patient. There were also electrophysiological features compatible with myoclonus (i.e., absence of a clear peak in the EMG power spectrum) of cortical origin (i.e., EEG-EMG coherence in a frequency range and presence of cortical drive), like has been demonstrated in patients with familial cortical myoclonic tremor with epilepsy (FCMTE) [[4]]. These cases illustrate that treatment of cortical myoclonic tremor after CAR T-cell therapy is probably dependent on the clinical setting.
- Subjects
MYOCLONUS; CHIMERIC antigen receptors; TREMOR; T cells; CONTRAST-enhanced magnetic resonance imaging
- Publication
Journal of Neurology, 2022, Vol 269, Issue 9, p5165
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-022-11127-6